The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines
Open accessAbstract
The current COVID-19 pandemic is a massive source of global disruption, having led so far to two hundred and fifty million COVID-19 cases and almost five million deaths worldwide. It was recognized in the beginning that only an effective vaccine could lead to a way out of the pandemic, and therefore the race for the COVID-19 vaccine started immediately, boosted by the availability of the viral sequence data. Two novel vaccine platforms, based on mRNA technology, were developed in 2020 by Pfizer-BioNTech and Moderna Therapeutics (comirnaty® and spikevax®, respectively), and were the first ones presenting efficacies higher than 90%. Both consisted of N1-methyl-pseudouridine-modified mRNA encoding the SARS-COVID-19 Spike protein and were delivered with a lipid nanoparticle (LNP) formulation. Because the delivery problem of ribonucleic acids had been known for decades, the success of LNPs was quickly hailed by many as the unsung hero of COVID-19 mRNA vaccines. However, the clinical trial efficacy results of the Curevac mRNA vaccine (CVnCoV) suggested that the delivery system was not the only key to the success. CVnCoV consisted of an unmodified mRNA (encoding the same spike protein as Moderna and Pfizer-BioNTech’s mRNA vaccines) and was formulated with the same LNP as Pfizer-BioNTech’s vaccine (Acuitas ALC-0315). However, its efficacy was only 48%. This striking difference in efficacy could be attributed to the presence of a critical RNA modification (N1-methyl-pseudouridine) in the Pfizer-BioNTech and Moderna’s mRNA vaccines (but not in CVnCoV). Here we highlight the features of N1-methyl-pseudouridine and its contributions to mRNA vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Melton, D. A., Krieg, P. A., Rebagliati, M. R., Maniatis, T., Zinn, K., & Green, M. R. (1984) · Nucleic Acids Research · doi:10.1093/nar/12.18.7035 · Cited by 6,324
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
MODOMICS: a database of RNA modification pathways. 2017 update
Boccaletto, P., Machnicka, M. A., Purta, E., Piątkowski, P., Bagiński, B., Wirecki, T. K., de Crécy-Lagard, V., Ross, R., Limbach, P. A., Kotter, A., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1030 · Cited by 1,782
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs
Krieg, P. A., & Melton, D. A. (1984) · Nucleic Acids Research · doi:10.1093/nar/12.18.7057 · Cited by 1,533
Overcoming cellular barriers for RNA therapeutics
Dowdy, S. F. (2017) · Nature Biotechnology · doi:10.1038/nbt.3802 · Cited by 1,139
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707304114 · Cited by 1,073
mRNA is an endogenous ligand for toll-like receptor 3
Karikó, K., Ni, H., Capodici, J., Lamphier, M., & Weissman, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310175200 · Cited by 1,062
Pseudouridine profiling reveals regulated mRNA pseudouridylation in yeast and human cells
Carlile, T. M., Rojas-Duran, M. F., Zinshteyn, B., Shin, H., Bartoli, K. M., & Gilbert, W. V. (2014) · Nature · doi:10.1038/nature13802 · Cited by 1,021
Transcriptome-wide Mapping Reveals Widespread Dynamic-Regulated Pseudouridylation of ncRNA and mRNA
Schwartz, S., Bernstein, D. A., Mumbach, M. R., Jovanovic, M., Herbst, R. H., León-Ricardo, B. X., Engreitz, J. M., Guttman, M., Satija, R., Lander, E. S., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.028 · Cited by 999
Sheikh, A., McMenamin, J., Taylor, B., & Robertson, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01358-1 · Cited by 939
Cationic liposome-mediated RNA transfection.
Malone, R. W., Felgner, P. L., & Verma, I. M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.16.6077 · Cited by 911
Modified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
Abu-Raddad, L. J., Chemaitelly, H., & Butt, A. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2104974 · Cited by 899
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884
Andries, O., Mc Cafferty, S., De Smedt, S. C., Weiss, R., Sanders, N. N., & Kitada, T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.051 · Cited by 701
SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
Kyriakidis, N. C., López-Cortés, A., González, E. V., Grimaldos, A. B., & Prado, E. O. (2021) · npj Vaccines · doi:10.1038/s41541-021-00292-w · Cited by 698
Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation
Anderson, B. R., Muramatsu, H., Nallagatla, S. R., Bevilacqua, P. C., Sansing, L. H., Weissman, D., & Karikó, K. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq347 · Cited by 682
Patisiran: First Global Approval
Hoy, S. M. (2018) · Drugs · doi:10.1007/s40265-018-0983-6 · Cited by 614
Opportunities and Challenges in the Delivery of mRNA-Based Vaccines
Wadhwa, A., Aljabbari, A., Lokras, A., Foged, C., & Thakur, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020102 · Cited by 584 · cited 1×
“It was reported that Ψ-modified transcripts, coding for four transcription factors (KLF4, c-MYC, OCT4, and SOX2), were successfully used to reprogram human cells to pluripotency with great efficiency (Warren et al., 2010).”
BackgroundNanomaterial Delivery Systems for mRNA Vaccines
Buschmann, M. D., Carrasco, M. J., Alishetty, S., Paige, M., Alameh, M. G., & Weissman, D. (2021) · Vaccines · doi:10.3390/vaccines9010065 · Cited by 582
Pseudouridine in RNA: What, Where, How, and Why
Charette, M., & Gray, M. W. (2000) · IUBMB Life · doi:10.1080/152165400410182 · Cited by 575
Thess, A., Grund, S., Mui, B. L., Hope, M. J., Baumhof, P., Fotin-Mleczek, M., & Schlake, T. (2015) · Molecular Therapy · doi:10.1038/mt.2015.103 · Cited by 556 · cited 1×
“At that time, the consensus in the medical field was that a safe and effective vaccine would need at least 12–18 months to be developed (Thorp, 2020).”
The tangled history of mRNA vaccines
Dolgin, E. (2021) · Nature · doi:10.1038/d41586-021-02483-w · Cited by 542
Pardi, N., Hogan, M. J., Naradikian, M. S., Parkhouse, K., Cain, D. W., Jones, L., Moody, M. A., Verkerke, H. P., Myles, A., Willis, E., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171450 · Cited by 530
The promise of mRNA vaccines: a biotech and industrial perspective
Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S., & DeRosa, F. (2020) · npj Vaccines · doi:10.1038/s41541-020-0159-8 · Cited by 498 · cited 1×
“This technology made possible a fast pace of discovery and manufacturing, critical features that could be fully utilized in a biotech and pharmaceutical setting (Jackson et al., 2020).”
BackgroundInduction of virus‐specific cytotoxic T lymphocytes in vivo by liposome‐entrapped mRNA
Martinon, F., Krishnan, S., Lenzen, G., Magné, R., Gomard, E., Guillet, J., Lévy, J., & Meulien, P. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230749 · Cited by 473 · cited 1×
“Although lower doses (50 and 25 µg) of Moderna’s modified mRNA-1273 can still elicit a significant immune response (Chu et al., 2021; Mateus et al., 2021), they remain much higher than the doses of CVnCoV unmodified mRNA vaccine.”
BackgroundModifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines
Nance, K. D., & Meier, J. L. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00197 · Cited by 466
RIBONUCLEIC ACIDS FROM YEAST WHICH CONTAIN A FIFTH NUCLEOTIDE
Davis, F. F., & Allen, F. W. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)70770-9 · Cited by 435
Stabilization of RNA stacking by pseudouridine
Davis, D. R. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.24.5020 · Cited by 399
Converting nonsense codons into sense codons by targeted pseudouridylation
Karijolich, J., & Yu, Y.-T. (2011) · Nature · doi:10.1038/nature10165 · Cited by 389
Self-citationLovejoy, A. F., Riordan, D. P., & Brown, P. O. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110799 · Cited by 380
Anderson, B. R., Muramatsu, H., Jha, B. K., Silverman, R. H., Weissman, D., & Kariko, K. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr586 · Cited by 356
Impact of mRNA chemistry and manufacturing process on innate immune activation
Nelson, J., Sorensen, E. W., Mintri, S., Rabideau, A. E., Zheng, W., Besin, G., Khatwani, N., Su, S. V., Miracco, E. J., Issa, W. J., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz6893 · Cited by 354
Nucleoside-5′-Phosphates from Ribonucleic Acid
COHN, W. E., & VOLKIN, E. (1951) · Nature · doi:10.1038/167483a0 · Cited by 335
Mateus, J., Dan, J. M., Zhang, Z., Moderbacher, C. R., Lammers, M., Goodwin, B., Sette, A., Crotty, S., & Weiskopf, D. (2021) · doi:10.1101/2021.06.30.21259787 · Cited by 327
Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells
(2021) · doi:10.1126/science.abj9853 · Cited by 327
A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA
Jeffs, L. B., Palmer, L. R., Ambegia, E. G., Giesbrecht, C., Ewanick, S., & MacLachlan, I. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-1873-z · Cited by 307
Diebold, S. S., Massacrier, C., Akira, S., Paturel, C., Morel, Y., & Reis e Sousa, C. (2006) · European Journal of Immunology · doi:10.1002/eji.200636617 · Cited by 283
Svitkin, Y. V., Cheng, Y. M., Chakraborty, T., Presnyak, V., John, M., & Sonenberg, N. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx135 · Cited by 278
The contribution of pseudouridine to stabilities and structure of RNAs
Kierzek, E., Malgowska, M., Lisowiec, J., Turner, D. H., Gdaniec, Z., & Kierzek, R. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1330 · Cited by 264
Pseudouridinylation of mRNA coding sequences alters translation
Eyler, D. E., Franco, M. K., Batool, Z., Wu, M. Z., Dubuke, M. L., Dobosz-Bartoszek, M., Jones, J. D., Polikanov, Y. S., Roy, B., & Koutmou, K. S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821754116 · Cited by 226
Chu, L., McPhee, R., Huang, W., Bennett, H., Pajon, R., Nestorova, B., & Leav, B. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.02.007 · Cited by 225
Translation of rabbit globin mRNA introduced by liposomes into mouse lymphocytes
DIMITRIADIS, G. J. (1978) · Nature · doi:10.1038/274923a0 · Cited by 212
Probst, J., Weide, B., Scheel, B., Pichler, B. J., Hoerr, I., Rammensee, H.-G., & Pascolo, S. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302964 · Cited by 206
In Vitro Transcription of Long RNA Containing Modified Nucleosides
Pardi, N., Muramatsu, H., Weissman, D., & Karikó, K. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-260-5_2 · Cited by 204
Weissman, D., Ni, H., Scales, D., Dude, A., Capodici, J., McGibney, K., Abdool, A., Isaacs, S. N., Cannon, G., & Karikó, K. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.8.4710 · Cited by 178
Meyer, M., Huang, E., Yuzhakov, O., Ramanathan, P., Ciaramella, G., & Bukreyev, A. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix592 · Cited by 178
Kremsner, P. G., Ahuad Guerrero, R. A., Arana-Arri, E., Aroca Martinez, G. J., Bonten, M., Chandler, R., Corral, G., De Block, E. J. L., Ecker, L., Gabor, J. J., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00677-0 · Cited by 172
Unusual base pairing during the decoding of a stop codon by the ribosome
Fernández, I. S., Ng, C. L., Kelley, A. C., Wu, G., Yu, Y.-T., & Ramakrishnan, V. (2013) · Nature · doi:10.1038/nature12302 · Cited by 172
Self-citationKis, Z., Kontoravdi, C., Shattock, R., & Shah, N. (2020) · Vaccines · doi:10.3390/vaccines9010003 · Cited by 159
OSTRO, M. J., GIACOMONI, D., LAVELLE, D., PAXTON, W., & DRAY, S. (1978) · Nature · doi:10.1038/274921a0 · Cited by 154
Pascolo, S. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.8.1285 · Cited by 152
Sculpting of the spliceosomal branch site recognition motif by a conserved pseudouridine
Newby, M. I., & Greenbaum, N. L. (2002) · Nature Structural Biology · doi:10.1038/nsb873 · Cited by 142
Padilla, R. M. (2002) · Nucleic Acids Research · doi:10.1093/nar/gnf138 · Cited by 142
Wurm, J. P., Meyer, B., Bahr, U., Held, M., Frolow, O., Kötter, P., Engels, J. W., Heckel, A., Karas, M., Entian, K., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp1189 · Cited by 128
N 1-Methylpseudouridine substitution enhances the performance of synthetic mRNA switches in cells
Parr, C., Wada, S., Kotake, K., Kameda, S., Matsuura, S., Sakashita, S., Park, S., Sugiyama, H., Kuang, Y., & Saito, H. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa070 · Cited by 127
Newby, M. I., & Greenbaum, N. L. (2001) · RNA · doi:10.1017/s1355838201002308 · Cited by 121
Investigation of Overhauser effects between pseudouridine and water protons in RNA helices
Newby, M. I., & Greenbaum, N. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202477199 · Cited by 111
From Antisense RNA to RNA Modification: Therapeutic Potential of RNA-Based Technologies
Adachi, H., Hengesbach, M., Yu, Y., & Morais, P. (2021) · Biomedicines · doi:10.3390/biomedicines9050550 · Cited by 92
Self-citationSynthetic Messenger RNA-Based Vaccines: From Scorn to Hype
Pascolo, S. (2021) · Viruses · doi:10.3390/v13020270 · Cited by 89
Nanoparticles as Adjuvants and Nanodelivery Systems for mRNA-Based Vaccines
Alfagih, I. M., Aldosari, B. N., AlQuadeib, B. T., Almurshedi, A. S., & Alfagih, M. M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010045 · Cited by 83
Suppression of Nonsense Mutations by New Emerging Technologies
Morais, P., Adachi, H., & Yu, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124394 · Cited by 71
Self-citationBrand, R. C., Klootwijk, J., Planta, R. J., & Maden, B. E. H. (1978) · Biochemical Journal · doi:10.1042/bj1690071 · Cited by 67
Chen, C., Zhao, X., Kierzek, R., & Yu, Y. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00531-10 · Cited by 63
Self-citationCureVac COVID vaccine let-down spotlights mRNA design challenges
Dolgin, E. (2021) · Nature · doi:10.1038/d41586-021-01661-0 · Cited by 61
Tomita, K. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.7.1683 · Cited by 59
Naylor, R. N., Ho, N. W. Y., & Gilham, P. T. (1965) · Journal of the American Chemical Society · doi:10.1021/ja01096a050 · Cited by 53
Ishii, K. J., & Akira, S. (2005) · Immunity · doi:10.1016/j.immuni.2005.08.003 · Cited by 41
PIANO: A Web Server for Pseudouridine-Site (Ψ) Identification and Functional Annotation
Song, B., Tang, Y., Wei, Z. C., Liu, G., Su, J., Meng, J., & Chen, K. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00088 · Cited by 37
Pseudouridines or how to draw on weak energy differences
Westhof, É. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.10.009 · Cited by 25
Roth, N., Schön, J., Hoffmann, D., Thran, M., Thess, A., Mueller, S. O., Petsch, B., & Rauch, S. (2021) · doi:10.1101/2021.05.13.443734 · Cited by 18
Kremsner, P. G., Guerrero, R. A. A., Arana, E., Aroca Martinez, G. J., Bonten, M. J. M., Chandler, R., Corral, G., De Block, E. J. L., Ecker, L., Gabor, J. J., et al. (2021) · doi:10.2139/ssrn.3911826 · Cited by 17
The future in an RNA molecule: from mRNA vaccines to therapeutics – An interview with Drew Weissman
Ruffell, D. (2021) · FEBS Letters · doi:10.1002/1873-3468.14190 · Cited by 9
Mechanisms and Clinical Applications of RNA Pseudouridylation
Morais, P., Adachi, H., Chen, J. L., & Yu, Y. (2021) · RNA technologies · doi:10.1007/978-3-030-71612-7_19 · Cited by 5
Self-citationHoerr, I. (2000) · doi:10.1002/1521-4141(200001)30:1
Cited by
Chemistry, structure and function of approved oligonucleotide therapeutics
Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 828
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 771
RNA modifications: importance in immune cell biology and related diseases
Cui, L., Ma, R., Cai, J., Guo, C., Chen, Z., Yao, L., Wang, Y., Fan, R., Wang, X., & Shi, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01175-9 · Cited by 405
Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects
Kon, E., Ad-El, N., Hazan-Halevy, I., Stotsky-Oterin, L., & Peer, D. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00811-9 · Cited by 371
Regulation and functions of non-m6A mRNA modifications
Sun, H., Li, K., Liu, C., & Yi, C. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00622-x · Cited by 278
Metadata
- Authors
- Morais, P., Adachi, H., & Yu, Y.-T.
- Venue
- Frontiers in Cell and Developmental Biology
- Publisher
- Frontiers Media SA
- Published
- 2021-11-04
- Volume
- 9
- Pages
- 789427-789427
- ISSN
- 2296-634X (ISSN-L)
- OpenAlex
- W3212789570
- Cited by
- 273
- References
- 83
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.